Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase Mutants-Reference-Cited by-同舟云学术

Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase Mutants

Published:2008-08-15 Issue:36 Volume:47 Page:9345-9354
ISSN:0006-2960
Container-title:Biochemistry
language:en
Short-container-title:Biochemistry

Author:

Marinello Jessica¹,Marchand Christophe¹,Mott Bryan T.¹,Bain Anjali¹,Thomas Craig J.¹,Pommier Yves¹

Affiliation:

1. Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, Maryland 20892, and NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892-3370

Publisher

American Chemical Society (ACS)

Subject

Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/bi800791q

Reference29 articles.

1. Zolopa, A., Mullen, M., Berger, D., Ruane, P., Hawkins, T., Zhong, L., Chuck, S., Enejosa, J., Kearney, B., and Cheng, A. (2007) The HIV integrase inhibitor GS-9137 demonstrates potent ARV activity in treatment-experienced patients,14th Conf. Retrovir. Opportun. Infect. Abstract, 143LB.

2. Raltegravir: an integrase inhibitor for HIV-1

3. HIV-1 integrase inhibitors: 2005–2006 update

4. Human cell proteins and human immunodeficiency virus DNA integration

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges;Drug Resistance Updates;2024-03

2. Quinolone: a versatile therapeutic compound class;Molecular Diversity;2022-12-17

3. Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance;Viruses;2022-11-22

4. High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients;International Journal of Molecular Sciences;2022-11-18

5. Design, synthesis and biological evaluation of novel 1, 3, 4-oxadiazole derivatives as potent neuraminidase inhibitors;Bioorganic & Medicinal Chemistry;2022-03